uniQure N.V. QURE 深 沪
已收盘 02-06 16:00:00 美东时间
25.655
+1.135
+4.63%
华盛通- 最 高28.77
- 今 开25.21
- 成交量 157.32万股
- 最 低 21.15
- 昨 收 24.52
- 总市值 119.67万
- 52周最高 71.50
- 市盈率 静 3.65
- 换手率 3372.54%
- 52周最低 7.76
- 委 比 -29.32%
- 总股本 4.66万
- 历史最高 82.49
- 量 比 0.70
- 振 幅 31.08%
- 历史最低 1.10
- 每 手 1
- 风险率 14.67%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Early uniQure Fabry Trial Shows Lasting Enzyme Boost, Safety Watch
uniQure shares early trial data showing strong enzyme increases in Fabry patients, manageable safety results, and paused higher dosing after liver enzyme findings.
今天 02:58
Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
2025-11-10 19:12
A Glimpse of uniQure's Earnings Potential
uniQure (NASDAQ:QURE) will release its quarterly earnings report on Monday, 202...
2025-11-08 01:05
Biohaven Stock Hits 52-Week Low, Cuts R&D Spending After FDA Rejection
Biohaven stock plunged after the FDA rejected Vyglxia for spinocerebellar ataxia, prompting major R&D cuts and a William Blair downgrade.
2025-11-06 01:53
Gold Edges Higher; ISM Manufacturing PMI Falls In October
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index fa...
2025-11-04 03:23
UniQure Shares Drop After FDA Shifts Stance On Huntington's Gene Therapy Data
UniQure shares fell after the FDA questioned the adequacy of data supporting its AMT-130 gene therapy for Huntington's disease, delaying BLA plans.
2025-11-04 02:04
Kimberly-Clark, Vertex And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining mor...
2025-11-03 21:14
华福证券-生物医药行业：看好创新药产业趋势，关注ESMO和医保谈判-251014
（来源：研报虎） 创新药大事回顾：1)uniQure基因疗法AMT-130亨廷顿病I/II期临床取得顶线结果：亨廷顿病是一种罕见常染色体显性遗传病，由位于...
2025-10-14 17:58
生物技术公司uniQure将公开发行股票筹资3亿美元
生物技术公司uniQure(QURE)早盘下跌2.6%，该公司将扩模后的3亿美元公开发行定价为每股47.50美元。所筹资金将支持公司持续进行临床试验和产品开发，巩固其在基因治疗市场的地位。 海量资讯、精准解读，尽在新浪财经APP 责任编辑：张俊 SF065
2025-09-26 22:49
uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer
uniQure appoints Kylie O’Keefe as Chief Customer and Strategy Officer to lead the commercialization of AMT-130, a gene therapy for Huntington’s disease. With extensive experience in rare diseases and gene therapy, O’Keefe will oversee global commercial strategy and execution for AMT-130, aiming for U.S. launch in 2026. Her leadership is expected to advance uniQure’s mission of addressing severe unmet medical needs.
2025-06-11 12:00
